Leukemias, lymphomas, and other hematologic cancers:
Indications for: Cladribine
Active hairy cell leukemia.
Adult Dosage:
Give by continuous IV infusion for 7 consecutive days. 0.09mg/kg per day.
Children Dosage:
See full labeling.
Boxed Warning:
Administer under the supervision of a qualified physician experienced in the use of antineoplastic therapy. Risk of neurological toxicity. Acute nephrotoxicity has been observed with high doses (esp. when concomitant with other nephrotoxic treatments).
Cladribine Warnings/Precautions:
Delay or discontinue if neurotoxicity or renal toxicity occurs. Myelosuppression. Active infection. Renal or hepatic insufficiency. Monitor blood counts (esp. during first 4–8 weeks post-dose), renal and hepatic function. Pregnancy (Cat.D), nursing mothers: not recommended.
Cladribine Classification:
Chlorinated purine nucleoside analog.
Cladribine Interactions:
Live attenuated vaccines: not recommended. Increased toxicity with myelosuppressive, immunosuppressive, or nephrotoxic agents.
Adverse Reactions:
Severe myelosuppression (eg, neutropenia, anemia, thrombocytopenia), fever, infection, fatigue, nausea, rash, headache, inj site reactions, others; neurotoxicity, nephrotoxicity, tumor lysis syndrome (rare).
Generic Drug Availability:
YES
How Supplied:
Contact supplier.
